Connect your AI

Neurocrine Biosciences NBIX Gross Profit

Gross Profit at other companies

Bristol-Myers SquibbBMY

$8.07B-1.2%

Acadia PharmaceuticalsACAD

$243.27M+8.6%

Crinetics PharmaceuticalsCRNX

$10.53M+2,818%

BiogenBIIB

$1.82B+0.8%

Rhythm Pharmaceuticals, Inc.RYTM

$52.96M+82.3%

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$814.5M+42.2%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

Market cap$17.3B+29.6%

Enterprise value$17.49B+28.9%

P/E25.9×-12.5×

P/S5.6×+0.3×

Profitability

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Calculated from Neurocrine Biosciences’s reported figures.

$814.5Mtotal revenue−$13.8Mtotal cost of revenue=$800.7M

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Neurocrine Biosciences's gross profit?: Neurocrine Biosciences (NBIX) reported gross profit of $800.7M in Q1 2026.
How has Neurocrine Biosciences's gross profit changed year-over-year?: Neurocrine Biosciences's gross profit increased by 42.1% year-over-year, from $563.4M to $800.7M.
What is the long-term trend for Neurocrine Biosciences's gross profit?: Over 4 years (2021 to 2025), Neurocrine Biosciences's gross profit has grown at a 25.9% compound annual growth rate (CAGR), from $1.12B to $2.81B.
What does gross profit mean?: Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.